Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Revenue for 6 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue rose 215.18% year-over-year to $1.8 million, compared with a TTM value of $34.0 million through Sep 2025, up 2931.61%, and an annual FY2024 reading of $2.6 million, changed N/A over the prior year.
  • Revenue was $1.8 million for Q3 2025 at X4 Pharmaceuticals, down from $2.0 million in the prior quarter.
  • Across five years, Revenue topped out at $28.8 million in Q1 2025 and bottomed at -$1.1 million in Q2 2023.
  • Average Revenue over 4 years is $2.4 million, with a median of -$176500.0 recorded in 2022.
  • The sharpest move saw Revenue fell 25.05% in 2023, then surged 250.44% in 2025.
  • Year by year, Revenue stood at -$1.1 million in 2022, then fell by 0.35% to -$1.1 million in 2023, then soared by 230.66% to $1.5 million in 2024, then grew by 17.67% to $1.8 million in 2025.
  • Business Quant data shows Revenue for XFOR at $1.8 million in Q3 2025, $2.0 million in Q2 2025, and $28.8 million in Q1 2025.